Josh Bleichman

Josh Bleichman asked about the level of physician and patient interest in ENDEAVOR Cohort 8 recruitment and the current extent of enrollment.

Answer

Executive VP, Chief Scientific Officer, and Head of Research and Development Louise Rodino-Klapac confirmed significant interest in Cohort 8. She stated that screening is ongoing, dosing is expected soon, and the company is on track to present data by the end of the year.

Josh Bleichman asked about the level of physician and patient interest in ENDEAVOR Cohort 8 recruitment and requested an update on the current extent of enrollment.

Answer

Louise Rodino-Klapac, Executive VP, Chief Scientific Officer, and Head of Research and Development, confirmed significant interest in Cohort 8. She stated that Sarepta is currently in the process of screening patients for enrollment and expects to present data by the end of 2026, indicating they are on track.